Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.052 | 0.7 |
mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | IU1 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |
mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.7 |
mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |